News

VLEVA's EU-subsidiemonitor 2021-2022; I3, het Interregional Innovation Investment Instrument

Published on | 4 months ago

Programmes EIE

In the 'EU-subsidiemonitor 2021-2022' VLEVA investigates how Flemish organisations participate in European subsidised programs. This time with a focus for Interregional Innovation Investment Instrument - I3

  • I3 finances International cooperations building innovative value chains

  • Discover how Flanders’ FOOD with the HIGHFIVE-project stimulates digital and green growth in the agrofood-value chain in Europe.

  • Get information on the open calls in I3

Deadline for strand 1 and strand 2a are both on december 5th 2024. Recordings of the information sessions can be found here.

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1523 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.